Videos

Daniel Soteres, MD, discusses KONFIDENT-S data showing sebetralstat improved quality of life for HAE patients already stable on long-term prophylaxis.

The latest episode of Moving the Needle in Medicine features Philip Adamson, MD, MSc, as he discusses upcoming advancements in heart failure care.

The latest episode of Moving the Needle in Medicine features Philip Adamson, MD, MSc, as he walks through his long and successful career in cardiology.

Daniel Soteres, MD, discusses KONFIDENT-S data showing sebetralstat quickly resolves breakthrough HAE attacks in patients on long-term prophylaxis

Telehealth stepped alcohol treatment reduced weekly drinking, but not the primary endpoint, among patients with chronic liver disease.

David B.K. Golden, MD, of Johns Hopkins, discusses anaphylaxis counseling, the Anaphylm CRL, and why a new epinephrine guideline is still years away.

GLP-1 receptor agonists show early promise for psoriasis and HS, but 3 experts urge caution on mechanism, durability, and long-term safety.

Ron Blankstein, MD, explains the value of PCD-CT and its consistency in both data collection and analysis of plaque with prior technology.

IgA nephropathy shows a male predominance, but researchers have not identified why. Ramy Hanna, MD explores possible biological explanations.

Jason Hawkes, MD, explains how targeted therapies are advancing precision medicine and reshaping personalized care for atopic dermatitis.

Most newer nonsteroidal topical options are now approved for children as young as 2 years. Linda Stein Gold, MD, discusses adherence and misconceptions of pediatric AD.

New topical mechanisms introduce more ways to control pediatric AD without the sting, burn, or long-term steroid concerns that limit adherence, Linda Stein Gold, MD, says.

Amy Paller, MD, highlights takeaways from the recent FDA approval of risankizumab-rzaa (Skyrizi) for children with psoriasis and PsA.

Ron Blankstein, MD, discusses a recent study confirming the replicability of CCTA results with AI-CPA in patients with coronary plaque at risk of cardiovascular disease.

Exa-cel requires careful counseling on treatment timelines, chemotherapy conditioning, fertility risks, and the gene therapy journey.

Haydar Frangoul, MD, discusses how the expanded indication may allow earlier conversations about curative therapy and intervention before irreversible complications develop.

Ron Blankstein, MD, discusses a secondary analysis of Heartflow’s DECIDE registry, indicating undetected cardiovascular risk in patients previously labeled safe.

Kimberly Blumenthal, MD, discusses who qualifies for de-labeling and how risk stratification guides testing.

ORIGIN 3 investigator brings atacicept approval to BAFF/APRIL targeting to IgAN

Ashish Rana, MD, discusses Sermo’s recent clinician survey, which highlighted patients’ use of unapproved and compounded GLP-1 medications.

Kimberly Blumenthal, MD, MSc, explains how surgical dyes, antibiotic-coated implants, and more can trigger perioperative anaphylaxis without appearing in the chart.

Sanjay Rajagopalan, MD, discusses the need for more patient-specific air pollution warnings to optimize accessibility for all individuals.

Erythema was less frequent with combination therapy than with phototherapy alone, according to Giovanni Leone, MD.

Ann Marie Navar, MD, PhD, discusses the groundbreaking approval of the first oral PCSK9 inhibitor and what it means for patients managing their LDL-C levels.

Michael Richards, MD, discusses aldosterone's role in CKD pathophysiology and why targeting this pathway may reshape kidney disease treatment.

Thanai Pongdee, MD, discusses 4-year PIONEER data showing avapritinib's quality of life, symptom, and safety benefits in indolent systemic mastocytosis remain durable.

NYU Langone’s Conor Donnelly, Allan Massie, and Michal Mankowski explain why follow-up after kidney transplant referral is critical to improving access.

Seth Martin, MD, MHS, discusses his recent study, which produced an AI-optimized equation that only requires 1 line of code.